FY2027 EPS Estimates for IceCure Medical Reduced by Analyst

IceCure Medical Ltd (NASDAQ:ICCM) – Stock analysts at Brookline Capital Management reduced their FY2027 EPS estimates for IceCure Medical in a research report issued on Thursday, March 27th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of $0.22 per share for the year, down from their prior estimate of $0.23. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.32 EPS and FY2029 earnings at $0.42 EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a report on Friday.

IceCure Medical Stock Performance

Shares of ICCM opened at $1.11 on Monday. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. IceCure Medical has a 52-week low of $0.48 and a 52-week high of $1.66. The stock has a 50 day moving average price of $1.32 and a 200 day moving average price of $0.99. The company has a market capitalization of $61.61 million, a price-to-earnings ratio of -3.83 and a beta of 0.37.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.07 million.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC increased its stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,453 shares of the company’s stock after buying an additional 14,893 shares during the quarter. Geode Capital Management LLC owned about 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.